• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Cinven to acquire Mercury Pharma

Cinven to acquire Mercury Pharma

August 17, 2012
CenterWatch Staff

Cinven, a European private equity firm, reached agreement to acquire Mercury Pharma, an international specialty pharmaceutical company, from owner HgCapital.

"We identified niche and branded pharmaceuticals as an attractive segment and, within that, Mercury as a strongly performing business,” said Supraj Rajagopalan, a partner at Cinven. “In addition to its excellent existing product portfolio and pipeline—both of which should drive strong organic growth—it is a fantastic platform for further consolidation both in the UK and internationally. Our in-depth knowledge of this sector, given our long-term focus on healthcare, has enabled us to identify a number of compelling acquisition opportunities which we hope to execute in the early stages of our investment."

Headquartered in Croydon, U.K., Mercury has operational bases in the U.K., Ireland and India. The company, which has generated strong revenue growth in recent years, markets niche and branded pharmaceuticals and has a broad portfolio of well-established products including treatments for thyroid disorders, pain, arthritis, pulmonary arterial hypertension and cardiovascular diseases, as well as a number of anaesthesia products.

"In the past two years, the Mercury business has been streamlined to refocus on its core specialty pharmaceutical products,” said John Beighton, CEO of Mercury Pharma. “We have a well-diversified product range and are investing in creating a pipeline of further specialist medicines. Our 15 new products launched in 2011-12 are already starting to show earnings momentum and we have a strong product pipeline. Despite the current economic environment, our products and company are extremely well positioned."

Rajagopalan of Cinven added, "Our investment in Mercury demonstrates our focus on acquiring European-based companies with significant international growth prospects, as well as our ability to originate investments through our strong sector focus."

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing